05 Oct 2026
Correction Clarification Regarding Annual Report 2026 Liven Pharma Limited has issued a clarification regarding typographical errors in its Annual Report for the year ended June 30, 2026, correcting the year in the Statement of Compliance from 2025 to 2026 and amending a heading in the Notice of General Meeting from Six Months to Annual. Meetings 05 Oct 2026
Notice of Annual General Meeting REVISED Liven Pharma Limited has issued a notice for its Annual General Meeting (AGM) scheduled for October 26, 2026, to consider financial statements, appoint auditors, and transact other routine business. Share transfer books will remain closed from October 19 to October 26, 2026. Meetings 05 Oct 2026
Notice of Annual General Meeting REVOKED Liven Pharma Limited has issued a notice for its Annual General Meeting (AGM) to be held on Monday, October 26, 2026, at its registered office and via weblink to consider six-month audited accounts for the period ended June 30, 2026, appoint auditors, and transact other routine business. The share transfer books will remain closed from October 19 to October 26, 2026. Meetings 05 Oct 2026
financial results for the Year Ended June 30, 2026 Liven Pharma Limited reported its annual financial results for the year ended June 30, 2026, showing a net loss after tax of PKR 31.14 million compared to a loss of PKR 584.46 million in the previous year. Sales decreased to PKR 105.81 million from PKR 127.27 million YoY, while the loss per share improved to PKR 0.28 from PKR 7.11. Financials 05 Oct 2026
Transmission of Annual Report for the Year Ended June 30, 2026 Liven Pharma Limited reported its annual financial results for the year ended June 30, 2026, recording a net loss after tax of PKR 31.139 million compared to a loss of PKR 584.459 million in the previous year. The Board has decided to withhold dividend distribution for the year in light of prevailing financial headwinds and to prioritize business growth. Financials 02 Oct 2026
Board meeting in Progress Liven Pharma Limited announced that its board meeting scheduled for October 2, 2026, to consider financial results and related matters is currently in progress. The decisions of the board will be communicated subsequently as per regulatory timelines. Meetings 25 Sep 2026
Board Meeting Liven Pharma Limited has announced that a meeting of its Board of Directors will be held on October 2, 2026, to consider the Annual Accounts for the period ended June 30, 2026, and potential entitlements. A closed period is in effect from September 25, 2026, to October 2, 2026. Meetings 27 Aug 2026
Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations Kaashif Hussain Siddique (Executive Director of Liven Pharma Limited) executed multiple share sale transactions totaling 14,416 shares in the ready market between January and February 2026, as disclosed under PSX Regulation 5.6.4. Insiders 15 Jul 2026
Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations OTHERS 14 Jul 2026
Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations OTHERS 14 Jul 2026
Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations OTHERS 24 Jun 2026
MATERIAL INFORMATION SIGNING OF MOU WITH TOFFLON THE TECH GIANT OF CHINA OTHERS 29 Apr 2026
Financial Results for the 3rd Quarter Ended 31st March 2026 Financials 23 Apr 2026
Board Meeting for the 3rd Quarter Financials of 2025-26 Liven Pharma Limited has scheduled a Board of Directors meeting for April 29, 2026, to review the quarterly financial accounts for the period ended March 31, 2026, and to consider the declaration of any entitlements. A closed period for trading in company shares by directors, the CEO, and executives is in effect from April 23, 2026, to April 29, 2026. Meetings 11 Mar 2026
Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations OTHERS 11 Mar 2026
Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations OTHERS 11 Mar 2026
Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations OTHERS 11 Mar 2026
Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations Kaashif Hussain Siddique, an Executive Director of Liven Pharma Limited, purchased a total of 29,500 shares across multiple transactions on March 3 and March 4, 2026, pursuant to PSX Regulation 5.6.4. Insiders 09 Mar 2026
Condensed Interim Financial Statements for the Half Year ended December 31, 2025 (with shariah compliant disclosure) Financials 27 Feb 2026
Condensed Interim Financial Statements for the Half Year ended December 31, 2025. Financials 
